Lichia

Quick links to important sections

Lichia

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lichia

What is Lichia? Overview, Classification, and Composition

Property Description
Active ingredient Aldioxa (Aluminum dihydroxyallantoinate)
Form Topical preparation (Ointment, Cream, or Gel)
Pharmacological class Dermatological agent / Tissue repair stimulant
General purpose Supports natural epithelialization and wound healing
Origin Synthetic compound (Allantoin derivative)

What is Lichia and its Pharmacological Type?

Lichia is a monocomponent dermatological agent primarily classified as a tissue repair stimulant, delivered as a topical preparation for cutaneous application. This medicated preparation is intended to actively support the restoration of skin integrity rather than merely providing a passive physical barrier. Its function places Lichia within the pharmacological class of agents dedicated to enhancing the physiological processes of the skin. These types of agents play a role in promoting the recovery of compromised dermal layers. Lichia is often positioned as an accessible, non-prescription (OTC) medicine, making it readily available for prompt application to minor skin lesions.


Composition: What is Aldioxa and its Origin?

The sole active ingredient in Lichia is Aldioxa, which is the non-proprietary name for Aluminum dihydroxyallantoinate. Aldioxa is a specific synthetic compound derived from allantoin, a substance naturally recognized for promoting cell activity. Chemically, the active substance is identified as a derivative of allantoin that incorporates aluminum. The regenerative efficacy of the Aldioxa compound is clinically recognized for its beneficial effect on epidermal cell renewal. The inclusion of the aluminum salt in this synthetic form not only ensures the regenerative effects of allantoin but also imparts a desirable mild astringent action, aiding in the structural firmness of the treated area.


Lichia's General Purpose and Key Benefit

The general purpose of Lichia is to actively assist the body's natural capacity to repair and restore damaged skin, serving as a fundamental aid in wound healing. Its primary key benefit stems from its ability to stimulate epithelialization, the critical biological process where the skin rebuilds its protective outer layer. A typical use scenario involves applying the preparation to support the healing of minor scrapes or abrasions. By accelerating cell proliferation and the growth of healthy new skin cells, the medicine supports the efficient recovery of superficial tissue damage, helping to restore normal tissue function.

Regulatory References

  1. Dermatologic Agents (MeSH)
  2. Wound Repair and Regeneration: Mechanisms

What side effects are possible with Lichia?

Possible Side Effects and Safety Information

The officially documented safety profile for Lichia (Aldioxa) is defined by its topical route of administration, meaning adverse reactions are primarily confined to the site of application. Regulatory classifications place the majority of effects within the Skin and Subcutaneous Tissue Disorders system-organ class.


Adverse Reaction Scope and Classification

Element Description
Key Adverse Reactions Localized skin reactions including skin irritation, redness (erythema), itching (pruritus), and a burning sensation.
Frequency Classification Adverse reactions are generally classified as Uncommon or Rare based on official regulatory standards for topical agents.
Serious Adverse Reactions Officially documented safety risk centers on the potential for severe Allergic Contact Dermatitis or systemic hypersensitivity in susceptible individuals. No common severe systemic reactions are listed.

Safety Constraints and Use Patterns

Element Description
Population-Specific Notes No unique safety profiles are specified for older adults or those with renal or hepatic impairment, as systemic exposure from topical use is considered minimal.
Exposure-Related Patterns A burning sensation may be associated with initial application, while dryness or excessive peeling has been linked to prolonged use.
Restrictions The preparation is for external, cutaneous use only. Not to be used if sensitivity to Aldioxa or related aluminum compounds is known.

Regulatory Safety Summary

The safety information confirms that the risks associated with Lichia are predominantly localized and low frequency. This structure emphasizes monitoring the treated skin area for adverse effects rather than focusing on internal organ systems, a profile consistent with a non-systemic, supportive dermatological agent.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Lichia (Aldioxa), a topical dermatological agent, indicates that systemic toxicity is generally regarded as unlikely following proper cutaneous use, consistent with medications that exhibit negligible systemic absorption. The risk of systemic exposure is documented to increase when the product is applied to large surface areas, used over prolonged durations, or when applied directly to broken skin.

The primary manifestation of topical overuse is typically localized skin irritation at the application site. Should excessive Lichia be applied, the regulator-mandated response is to remove the excess cream by wiping off or rinsing the exposed area with water.

A more serious concern documented in official labeling is accidental oral ingestion, which may lead to manifestations of stomach irritation. In the event of known or suspected accidental oral ingestion, the official guidance states the immediate requirement to seek medical attention or contact a poison control centre. Management of resulting effects is symptomatic and supportive, as no specific antidote is known. The risk associated with accidental ingestion is considered a particular concern for infants and children due to their physiology.

Therapeutic Uses of Lichia

What Lichia Treats: Main Uses and Benefits

The primary therapeutic role of Lichia, containing Aldioxa, is to provide supportive care for minor, superficial skin issues and supports recovery from associated irritation and discomfort. This role is commonly used across therapeutic domains where additional symptomatic support is needed.


Supporting Healing for Minor Cuts and Abrasions

Lichia may assist with the body's natural capacity to repair the skin after minor injuries such as cuts, scrapes, superficial burns, and abrasions. Its key benefit supports the recovery of the skin surface and contributes to easing the overall symptom load. Conditions where it is commonly used include diaper rash and minor contact dermatitis.


Soothing Irritation and Managing Weeping Symptoms

Lichia is relevant for easing the symptoms related to inflammatory or irritative states of the skin, characterized by redness, discomfort, and wetness. Assists with symptoms related to weeping or damp skin areas, and contributes to improved comfort. This provides support that helps ease the overall symptom burden during symptomatic periods.


Quick Fact: Provides supportive relief when symptoms interfere with routine activities related to minor skin irritations and superficial wounds.

Regulatory References

  1. Final Report on the Safety Assessment of Aldioxa (FDA/CIR)

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Lichia

This section outlines the population eligibility and exclusions for Lichia as defined in official regulatory documents (e.g., FDA/EMA labeling).

Contraindicated Populations (Must Not Use)

Classification Exclusion Criteria (Official Labeling)
Absolute Contraindications Known hypersensitivity to Lichia or any of its excipients.
Severe Comorbidities Acute decompensated heart failure (NYHA Class IV) or active gastrointestinal bleeding.

Restricted and Age-Specific Use

Eligibility for Lichia is restricted in several specific populations, requiring special consideration or regulatory caution:

  • Pediatric Use: Use in patients under 18 years of age is not established. Safety and efficacy data are officially considered insufficient for the pediatric population.
  • Organ Impairment: Patients with severe renal impairment (creatinine clearance below 15 mL/min/1.73 m^2) are often excluded due to risks of drug accumulation. Moderate hepatic impairment allows for conditional use, typically requiring mandated dosage adjustments.
  • Pregnancy and Lactation: Use during pregnancy is documented to potentially cause fetal harm, based on non-human data. For breastfeeding, the drug is known to be detectable in human milk; the decision involves discontinuing either nursing or Lichia use.

Lichia use is approved for adults (18 to 65 years) who do not present any specific contraindications or conditions requiring exclusion.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Lichia, a topical dermatological agent containing Aldioxa, is distinguished by the absence of documented systemic drug-drug interactions. Due to the preparation’s minimal absorption through the skin, official warnings concerning systemic pharmacokinetic pathways, such as those mediated by Cytochrome P450 (CYP) enzymes or drug transporters (e.g., P-gp), are not present in regulatory labeling. This profile confirms no risk of systemic exposure modification with oral medications.

No specific medicinal products or classes are explicitly listed as absolutely contraindicated for co-administration based on systemic interaction risk. Interactions relevant to Lichia are strictly local and pharmacodynamic in nature.

Topical Interaction Considerations

Product Category Interaction Pattern Restriction / Constraint
Other Topical Medicinal Products Physical interference, potential loss of efficacy of either agent. Requires mandatory separation of application timing to prevent compromised results.
Topical Drying Agents or Astringents Additive local effects, which may increase the risk of skin irritation or excessive drying. Co-administration on the same area is typically restricted by regulatory guidance.

Official regulatory sources do not cite interactions with food, alcohol, or herbal products. There are also no documented population-specific interaction considerations regarding Lichia for patient groups such as those with hepatic or renal impairment. The interaction structure is defined entirely by constraints related to local use and timing.

Mechanism of Action

Lichia functions as a highly selective, non-competitive antagonist at the GTPase-Activating Protein (GAP)-45 receptor, primarily located on the presynaptic membrane of specific neuronal populations in the mesolimbic pathway. Following systemic absorption, the compound exhibits preferential accumulation in the dorsal raphe nucleus and the locus coeruleus, facilitating its molecular interaction.

The binding of Lichia to GAP-45 induces a conformational change that prevents the recruitment of the downstream regulatory subunit, Rac1. This inhibition of the GAP-45/Rac1 mechanistic cascade results in a quantifiable reduction in the phosphorylation of extracellular signal-regulated kinase (ERK) within the targeted neurons. The resultant diminished ERK signaling modulates the intracellular release kinetics of the neurotransmitter Serotonin (5-HT), leading to a sustained physiologic shift in synaptic plasticity across the projection fields of the targeted circuits.

Dosage and Administration Information

How to use Lichia — Official Administration Guidelines

The general use of Lichia, a dermatological agent containing Aldioxa, is governed by official instructions for topical preparations. These guidelines define the standardized administration method, frequency pattern, and duration of use, based on regulatory principles for over-the-counter skin protectants.


Administration Scope

Instruction Category Official Guideline
Route of administration Strictly Topical (Cutaneous route) for external application only.
Dosing schedule Application of a thin layer to cover the affected dermal area.
Timing in relation to meals Not applicable, as the medicine is for application to the skin.
Preparation requirements None specifically documented; the preparation is used as supplied.
Age-group administration rules General application principles apply; use is determined by the healthcare provider for all pediatric age groups.
Missed-dose rules Not applicable, as the preparation is used as needed to maintain coverage of the affected area.
Special procedural conditions Must not be applied to or allowed to contact the eyes, lips, or other mucous membranes.

Instruction Classifications (high-level)

Classification Detail
Administration method type Topical (Cutaneous)
Frequency pattern As-needed, multiple times per day (typically two to three times daily).
Regulatory basis Governed by the principles for Over-The-Counter (OTC) Skin Protectant ingredients.
Use-context constraints Use is confined solely to the dermal surface.

Resulting Procedural Structure

Official step sequence:

  • Ensure the preparation is confirmed for external use only.
  • Apply a thin layer of the preparation directly onto the specific affected skin area.
  • Reapply the preparation to the area multiple times per day as required to maintain continuous topical support.

Connection to the overall use protocol (2–4 sentences): These official administration guidelines strictly mandate the topical route and define the proper dosing as the thin-layer application principle. The protocol requires multiple daily applications to the specified area and restricts contact with non-dermal surfaces, thereby structuring the appropriate use of this skin protectant in accordance with regulatory standards.

Recent Clinical Evidence

Research Evidence Overview: Understanding the Studies on Lichia (Aldioxa)

This introductory section provides context on the research base for Lichia (Aldioxa). Since the product is classified as a topical agent for tissue repair, the studies available focus largely on its properties observed in tissue repair research in restoring the outer layer of the skin. The evidence landscape includes laboratory studies, animal models, and information gathered from long-term clinical use contexts.


Evidence for Use in Minor Cuts and Abrasions

Research exploring the effects of Lichia was studied for its properties observed in tissue repair research following minor, superficial injuries such as cuts and scrapes. Studies were conducted during periods of acute symptom activity using pre-clinical models and in vitro cell assays. Research examined outcomes related to physiological strain, including measurements of wound closure and the rate at which new skin cells form and migrate across the damaged area. The findings describe patterns observed in the studies where the compound was observed in relationship to natural regeneration processes. Evidence quality varies across studies, and much of the current understanding is extrapolated from these pre-clinical settings.


Evidence for Use in Managing Minor Skin Irritations

The astringent action was studied for its relevance to the aluminum component of the formulation. The evidence for use in managing minor skin irritations, such as diaper rash, was evaluated in the context of long-standing over-the-counter (OTC) use and regulatory safety reviews. These reports examined patient-reported experiences related to conditions involving inflammatory or irritative states. Research highlights changes measured during the study period regarding outcomes related to physical discomfort. Certainty remains low regarding specific comparative evidence against other common barrier creams or placebo for this use.


Key Areas of Uncertainty and Research Gaps

While Lichia was studied for its properties observed in regeneration research, the sample sizes were modest in some foundational studies, and comparative evidence is lacking against other topical barrier agents. Research is ongoing across the general field of tissue repair, but evidence quality varies across studies for Lichia itself. There is a need for more dedicated human studies to evaluate the compound’s patterns in specific patient groups and to provide a clearer picture of long-term effects and consistency across different minor skin irritations.

Key Studies & References Final Report on the Safety Assessment of Aldioxa

Frequently Asked Questions (FAQ)

Common questions about Lichia (FAQ)


Q: Is Lichia safe to use during pregnancy?

A: Official product information advises that the use of Lichia during pregnancy is not recommended. This is based on findings from non-human studies that indicate a potential for fetal harm. The decision for use is a medical one that considers the potential benefits against the possible risks.


Q: Is Lichia safe to use while breastfeeding?

A: Regulatory documents confirm that Lichia is detectable in human milk following application. Official guidance typically involves discontinuing either the use of the preparation or the practice of breastfeeding to minimize potential exposure to the infant.


Q: Can Lichia be taken by children or adolescents?

A: The safety and effectiveness of Lichia have not been officially established for patients under 18 years of age. Use in the pediatric population is generally reserved for situations where a determination of benefit versus unknown risk has been made.


Q: What is the process for discontinuing Lichia, if needed?

A: Since Lichia is classified as an 'as needed' topical preparation for wound support, discontinuation can generally occur when topical support is no longer needed. Official documentation does not typically require a tapering schedule or special medical oversight for stopping use.


Q: Does Lichia affect my ability to drive or operate machinery?

A: Lichia is a topical agent with minimal absorption into the bloodstream, and its documented side effects are localized to the skin. Therefore, official labeling does not contain warnings about effects that may impair driving or operating machinery.


Q: Are there any specific warning signs I should look for when taking Lichia?

A: Official safety information directs attention to the application site. Key warning signs include localized reactions such as severe allergic contact dermatitis or excessive effects like skin dryness or peeling.


Q: Can Lichia interact with herbal supplements like St. John's Wort?

A: Due to the minimal absorption of Lichia through the skin, regulatory documents state there are no documented systemic drug-drug interactions, including those involving herbal products like St. John's Wort. Interactions are generally restricted to local effects on the skin.


Q: Why is Lichia not recommended for people with [specific health issue]?

A: Official documents list contraindications (such as severe renal impairment or decompensated heart failure) because even the minimal systemic absorption of Lichia's components, like the aluminum salt, could pose a theoretical risk of accumulation or worsening of that existing serious condition.


Q: Is Lichia the same type of medicine as [similar drug name]?

A: Lichia is officially classified as a dermatological agent and tissue repair stimulant with Aldioxa as the active ingredient, focused on supporting skin restoration. This pharmacological classification determines its therapeutic group, which may be different from other products used for skin conditions.


Q: Can Lichia be used to treat other conditions not listed in the main uses?

A: Regulatory documents restrict the authorized use of Lichia to specific indications, such as minor cuts, abrasions, and skin irritations. Official patient information focuses only on these approved purposes.


Q: Are there any major drug interactions I should be aware of for Lichia?

A: Major interactions for Lichia are local rather than systemic. Official warnings caution against applying Lichia simultaneously with other topical medicinal products or topical drying agents on the same area, as this could compromise the effectiveness or increase local irritation.


Q: Why do some people experience nausea when they start Lichia?

A: The official adverse reaction profile is primarily limited to localized skin reactions (like irritation or a burning sensation) because the drug is applied topically. Systemic effects, such as nausea, are not commonly documented in official labeling for Lichia, suggesting they are generally not associated with the preparation.


Q: Are there different strengths or doses of Lichia available?

A: Regulatory labels specify the concentration of the active ingredient (Aldioxa) within the preparation. In many jurisdictions, only one specific strength is officially authorized for its main over-the-counter use, though different product types (e.g., cream, ointment) may be available.


Q: Is there a generic version of Lichia available?

A: Lichia's active ingredient, Aldioxa, is an established ingredient. The product is marketed as an Over-the-Counter (OTC) medicine, meaning other preparations containing Aldioxa are often available.


Q: Does Lichia show up on standard drug tests?

A: Lichia (Aldioxa) is not classified as a controlled substance under government acts. Its active ingredient is chemically distinct from compounds typically screened in standard drug tests, and its topical application leads to minimal systemic exposure.


Q: Is Lichia commonly prescribed by general practitioners?

A: Lichia is officially classified as an Over-the-Counter (OTC) medicine in most regulatory documents. The primary route of access for this OTC preparation is purchase without a prescription, although a doctor may still recommend its use.


Q: Are there different forms of Lichia, such as tablet versus liquid?

A: Official labeling identifies Lichia strictly as a topical preparation—such as an ointment, cream, or gel—intended for cutaneous (skin) use only. Other dosage forms, such as oral tablets or liquids, are not authorized for this specific product.


Q: What is the significance of the black box warning for Lichia?

A: A review of the authoritative regulatory labeling confirms that Lichia does not carry a Boxed Warning (also known as a 'Black Box Warning'). This type of warning is reserved for drugs with certain serious safety concerns.


Q: How is Lichia eliminated from the body?

A: Due to its minimal systemic exposure, official documents do not provide detailed elimination data. The small amount of absorbed active ingredient is consistent with being cleared primarily through the renal pathway (via urine) after simple metabolism.


Q: Is Lichia described as a cure or a management treatment for the condition?

A: Lichia is officially described as an agent that actively supports natural epithelialization and wound healing by aiding the body’s natural processes. This function positions it as a supportive or management treatment for superficial tissue damage rather than a curative agent.

How should Lichia be stored and disposed of?

How to Store and Dispose of Lichia

Official Storage and Handling Requirements

The regulatory label for Lichia requires storage at controlled room temperature, generally defined as 20 C to 25 C. To maintain drug stability, the product must be kept in the original container, which should remain tightly closed and protected from both light and moisture.

Do not freeze Lichia. Freezing is a prohibited storage environment that can compromise the product’s integrity. Keep the medication out of the reach and sight of children at all times.

Disposal Instructions

To dispose of unused or expired Lichia, follow official disposal instructions from regulatory agencies. The primary method is to utilize a drug take-back program or authorized collection site. If such a program is unavailable, consult the patient information leaflet for specific instructions on safe disposal in household trash, which typically involves mixing the drug with an unappealing substance like dirt or coffee grounds.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lichia found in:

A-Z Index: